Gilead Sciences Valuation

Gilead Sciences retains regular Real Value of USD80.57 per share. The prevalent price of the corporation is USD68.57. At this time the corporation appears to be under valued. Macroaxis calculates value of Gilead Sciences from evaluating the corporation fundamentals such as Current Valuation of 6.82B, Return On Asset of 0.22% and Return On Equity of 0.85% as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage to acquire undervalued assets and to sell overvalued assets since at some point stocks prices and their ongoing real values will come together.

Gilead Science took a bad hit when their bet on a medical trial failed.  Subsequently, their stock price has come down considerably. But, the company is still profitable and is very focused on growth ahead.  Also, market forces should easily push the stock price higher than where it is when looked at from a price-to-earnings ratio.  For that matter, by any matrix, the stock is cheap and should go higher.  

Valuation Drivers Correlation

Selected Gilead Sciences Inc Valuation Data Over Time

Net Income Per Employee    Enterprise Value    Market Capitalization    
Investment Horizon     30 Days    Login   to change

Gilead Sciences Total Value Analysis

Gilead Sciences Inc is currently projected to have valuation of 6.82 B with market capitalization of 6.69 B, debt of 595.47 M, and cash on hands of 616.93 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Gilead Sciences fundamentals before making equity appraisal based on the enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
6.82 B6.69 B595.47 M616.93 M

Gilead Sciences Investor Information

About 83.0% of the company shares are owned by institutional investors. The company recorded earning per share (EPS) of 10.82. Gilead Sciences Inc last dividend was issued on 2017-03-14. This company had 2:1 split on January 28, 2013. Gilead Sciences Inc., a researchbased biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the AsiaPacific. To learn more about GILEAD SCIENCES call John Martin at 650 574-3000 or check out

Gilead Sciences Asset Utilization

Gilead Sciences harnesses its working resources almost 0.22 (percent), generating USD0.0022 for each dollar of working resources held by the corporation. An expanding assets utilization attests that the company is being more effective with each dollar of working resources it retains. In other words assets utilization of Gilead Sciences shows how effective it operates for each dollar spent on its working resources

Gilead Sciences Ownership Allocation (%)

Gilead Sciences secures a total of 1.56 Billion outstanding shares. Majority of Gilead Sciences outstanding shares are owned by outside corporations. These institutional investers are referred to non-private investors that are looking to purchase positions in Gilead Sciences to benefit from reduced commissions. Consequently, third-party entities are subject to different set of regulations than regular investors in Gilead Sciences Inc. Please pay attention to any change in the institutional holdings of Gilead Sciences as this could imply that something significant has changed or about to change at the company. Note that regardless of how profitable the company is, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns from it at some point.
 Ownership % 
Benchmark  Embed    Values 

Gilead Sciences Profitability Analysis

The company reported previous year revenue of 466.79 M. Net Income was 72.1 M with profit before overhead, payroll, taxes, and interest of 397.07 M.
Benchmark  Embed    Values 
Under Valued
April 27, 2017
Market Value
Downside upside
Real Value
Target Price Odds
 Above  Below  
Upside upside
Gilead Sciences is not too risky asset. Calculation of real value of Gilead Sciences is based on 1 month time horizon. Increasing Gilead Sciences time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.


Gilead Sciences Analyst Recommendations
Target PriceAdvice# of Analysts
Gilead Sciences Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Gilead Sciences Analyst Advice  

Tax Efficiency

Gilead Sciences Tax Efficiency History

Market Capitalization

Gilead Sciences Market Capitalization Analysis
Gilead Sciences Inc is rated # 5 in market capitalization category among related companies. Market capitalization of Pharmaceuticals And Biosciences industry is currently estimated at about 117.46 Billion. Gilead Sciences holds roughly 6.69 Billion in market capitalization claiming about 6% of equities listed under Pharmaceuticals And Biosciences industry.
Capitalization  Workforce  Revenue  Valuation  Total debt


Gilead Sciences Revenue
Based on latest financial disclosure Gilead Sciences Inc reported 466.79 M of revenue. This is 92.82% lower than that of the Healthcare sector, and significantly higher than that of Pharmaceuticals And Biosciences industry, The Revenue for all stocks is 95.26% higher than the company.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can includes product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.